#United States #San Diego #Eclipsebio #RNA QC #eSTRAND RNA QC

Eclipsebio Introduces Groundbreaking RNA Characterization Assay eSTRAND RNA QC™

On September 1, 2026, Eclipse Bioinnovations, Inc., a leader in sequencing analytics and AI-driven RNA therapeutic design, unveiled its innovative assay known as eSTRAND RNA QC™. This advanced technology dramatically enhances RNA characterization by employing nanopore-based sequencing, enabling drug developers to obtain critical insights into their RNA samples.

The Significance of RNA Characterization

Traditional methods for RNA characterization often yield limited data, posing challenges for biopharmaceutical developers striving to optimize therapeutic candidates. Classical assays typically fall short of providing comprehensive quality assessments, making it difficult for manufacturers to make informed decisions throughout their developmental processes. Recognizing this gap, Eclipsebio's eSTRAND RNA QC™ aims to set new standards by delivering a more detailed analysis through direct RNA sequencing.

How eSTRAND RNA QC™ Works

Eclipsebio's eSTRAND RNA QC™ harnesses the power of nanopore-based direct RNA sequencing, allowing it to accurately read full-length RNA sequences without necessitating reverse transcription or translation. This methodological advantage facilitates immediate characterizations of various critical attributes within RNA, such as:

• - RNA identity: Ensures the correctness of the RNA sequence.
• - Poly(A) tail length: Measures the integrity and stability of the RNA.
• - Capping efficiency: Evaluates the effectiveness of the cap structure crucial for protein synthesis.
• - Fragmentation hotspots: Identifies areas of RNA likely to degrade, which can inform stability and usage.
• - Double-stranded RNA analysis: Detects the presence of double-stranded molecules which may impact therapeutic performance.

By performing these simultaneous assessments within a single run, eSTRAND RNA QC™ significantly streamlines the testing process, enhancing the speed at which developers can advance their therapies to clinical trials.

Addressing the Industry’s Needs

Dr. Peter Chu, Co-Founder and CEO of Eclipsebio, commented on the pivotal nature of eSTRAND RNA QC™ by stating, "Low-resolution, single-dimensional insights from traditional characterization assays are not sufficient for today's drug development standards. eSTRAND RNA QC provides essential multi-attribute testing to provide partners the full scope of their RNA therapeutic quality." This sentiment underscores a growing demand in the biotech industry for more comprehensive molecular analyses to meet rising therapeutic standards.

A Vision for Future RNA Therapeutics

Eclipsebio's commitment to facilitating more effective RNA drug development through innovative analytics is evident in the capabilities of eSTRAND RNA QC™. Not only does it enhance the reliability of RNA therapeutics characterization, but it also signifies a move towards more efficient and rapid drug development processes overall.

As the biotechnology landscape continues to evolve, companies like Eclipsebio are setting important precedents in RNA sequencing and analytics, ultimately contributing to the advancement of therapeutic approaches for various diseases.

For more information on how eSTRAND RNA QC™ can advance RNA quality analysis, Eclipsebio encourages interested parties to reach out via their contact email for partners or the media.

About Eclipsebio

Headquartered in San Diego, Eclipse Bioinnovations, Inc. combines AI-powered design with rapid prototyping and sequencing analytics to fuel RNA drug development innovations. With immense expertise from early-stage basic research to preclinical therapeutic advancement, Eclipsebio positions itself as a vital partner in unlocking deeper insights into RNA and therapeutic biology. They offer expansive solutions as comprehensive partnerships for biopharma and as project-specific services for academic pursuits. To learn more about the company’s offerings, visit www.eclipsebio.com.